Navigation Links
Idenix Pharmaceuticals to Present at the PiperJaffray 20th Annual Health Care Conference
Date:11/25/2008

CAMBRIDGE, Mass., Nov. 25 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will participate in the PiperJaffray Annual Health Care Conference on Wednesday, December 3, 2008 at 4:30p.m. ET at The New York Palace Hotel in New York, NY.

The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replays will be available on the Idenix website for two weeks following the conference.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

    Idenix Pharmaceuticals Contact:
    Amy Sullivan 617-995-9838 (investors)
    Teri Dahlman 617-995-9905 (media)


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Idenix to Host Conference Call Discussing First Quarter 2008 Financial Results
3. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
4. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
5. Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
6. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
7. Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
8. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
11. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... , ... Providing for loved ones before one’s passing is of paramount importance. ... begin. “Now more than ever there are some questions that are far too critical ... said attorney Lisa Edgar Dickman, founder of the Law Offices of Lisa Edgar Dickman. ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... to experienced, personalized dental care since 1985. After thirty-two years, Dr. Latner has become ... privilege to help my numerous clients over the years with all their dental needs,” ...
(Date:4/21/2017)... Miami, Fl (PRWEB) , ... April 21, 2017 , ... ... Earth Day is a day to clean, plant trees and look forward to a ... green isn’t just about doing something outdoors. Indoor air quality can be two to ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal ... five common elements between the Obamacare program that most Republicans love to hate ... Warfarin poison to kill hogs. , Like Obamacare, the Miller program centers ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... a significant bandwidth upgrade infrastructure service to Tele-Media Solutions. IFN is delivering ... of IFN’s consortium member-owners, Tele-Media Solution’s protect transport with 3GB Dual Access Internet ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/18/2017)... 18, 2017  Cardinal Health (NYSE: CAH ... 2017 earnings per share (EPS) guidance and providing a ... in conjunction with this morning,s announcement of the planned ... Nutritional Insufficiency businesses. Cardinal Health now believes ... be at the bottom of its previous guidance range ...
Breaking Medicine Technology: